As IV-infused MSCs will also traffic to non-tumor tissues throughout the body, a prodrug strategy such as those engineered to be selectively activated by tissue- or tumor-specific proteases, such as prostate-specific antigen (PSA), will need to be exploited to prevent toxicity to non-target peripheral tissues [14, 53–56]. Here, KLK3 is linked to neoplasm.